<em id="hhyybl809"><legend id="yetuxx616"></legend></em><th id="wsingm687"></th><font id="uxidkd449"></font>

          <optgroup id="tsjcyv344"><blockquote id="fyfngf289"><code id="mcpaze367"></code></blockquote></optgroup>

          <span id="gwailk161"></span><span id="ngrjpk988"></span><code id="yhtdwu198"></code>
                    • <kbd id="ktpgqh259"><ol id="qtagkm049"></ol><button id="igoqir382"></button><legend id="ygsnih743"></legend></kbd>
                    • <sub id="bfqjzk481"><dl id="auqyno492"><u id="nukimw540"></u></dl><strong id="tjilzt847"></strong></sub>


                      International Market

                      Hansoh actively implements the internationalization strategy and has been committed itself to human being’s health with its professional expertise, through sales of internationally certified APIs and finished-dose pharmaceutical products to  the U.S. and other countries, and  international multi-center clinical trials for innovative drugs.   

                      Market Internationalization 

                      Multiple finished-dose pharmaceutical products and APIs are sold to the global market. 

                      R&D Internationalization 

                      Global multi-center clinical trials are under way simultaneously in the U.S. and China for HS-10296, a Category 1.1 innovative oncology drug, amid efforts for global expansion of innovative drugs.